Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2437) 2437
Publication (88) 88
Dissertation (57) 57
Book / eBook (33) 33
Conference Proceeding (14) 14
Newspaper Article (11) 11
Book Review (5) 5
Magazine Article (3) 3
Paper (3) 3
Book Chapter (1) 1
Data Set (1) 1
Electronic Resource (1) 1
Government Document (1) 1
Patent (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (811) 811
humans (372) 372
analysis (363) 363
animals (321) 321
materials science, multidisciplinary (287) 287
chemistry, multidisciplinary (262) 262
chemistry, physical (225) 225
male (204) 204
female (194) 194
research (189) 189
multidisciplinary sciences (165) 165
proteins (160) 160
mice (155) 155
physics, applied (141) 141
medicine (140) 140
research article (131) 131
nanoparticles (129) 129
nanoscience & nanotechnology (128) 128
expression (124) 124
biochemistry & molecular biology (120) 120
gene expression (120) 120
science (120) 120
cancer (119) 119
geosciences, multidisciplinary (119) 119
china (106) 106
studies (105) 105
pharmacology & pharmacy (99) 99
article (97) 97
plant sciences (97) 97
apoptosis (95) 95
health aspects (95) 95
energy & fuels (90) 90
genes (90) 90
middle aged (89) 89
cell line, tumor (86) 86
physiological aspects (84) 84
rats (83) 83
genetic aspects (82) 82
adult (80) 80
evolution (80) 80
physics, condensed matter (80) 80
cell biology (79) 79
growth (77) 77
identification (76) 76
oncology (76) 76
biology (75) 75
environmental sciences (72) 72
usage (72) 72
biotechnology & applied microbiology (71) 71
care and treatment (66) 66
activation (65) 65
chemistry, medicinal (64) 64
chemistry, analytical (63) 63
aged (62) 62
cells (62) 62
engineering, chemical (61) 61
graphene (61) 61
organic chemistry (61) 61
carbon (60) 60
methods (60) 60
nanostructure (60) 60
protein (60) 60
phylogeny (58) 58
genomes (57) 57
oxidative stress (56) 56
life sciences (55) 55
biotechnology (54) 54
electrochemistry (54) 54
chemistry (53) 53
design (53) 53
laboratories (53) 53
performance (53) 53
metabolism (52) 52
molecular structure (52) 52
chemical properties (51) 51
chemistry, applied (51) 51
gene-expression (51) 51
in-vitro (50) 50
plants (50) 50
signal transduction (50) 50
enzymes (49) 49
biochemistry (48) 48
mineralogy (48) 48
catalysis (47) 47
genetics & heredity (47) 47
mutation (47) 47
water (47) 47
films (46) 46
inhibition (46) 46
morphology (46) 46
dna (45) 45
geology (45) 45
polymers (45) 45
chemistry, organic (44) 44
geochemistry & geophysics (44) 44
model (44) 44
cells, cultured (43) 43
differentiation (43) 43
electrodes (43) 43
genomics (43) 43
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (8) 8
Engineering & Comp. Sci. - Stacks (7) 7
Collection Dvlpm't (Acquisitions) - Vendor file (5) 5
UTL at Downsview - May be requested (4) 4
Collection Dvlpm't (Acquisitions) - Closed Orders (3) 3
Earth Sciences (Noranda) - Stacks (3) 3
East Asian (Cheng Yu Tung) - Reference (3) 3
East Asian (Cheng Yu Tung) - Stacks (2) 2
Gerstein Science - Stacks (2) 2
Online Resources - Online (2) 2
Physics - Stacks (2) 2
UofT at Mississauga - Stacks (2) 2
Trinity College (John W Graham) - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2541) 2541
Chinese (21) 21
Spanish (2) 2
Arabic (1) 1
French (1) 1
German (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial
by Sun, Ying, Prof and Li, Wen-Fei, MD and Chen, Nian-Yong, Prof and Zhang, Ning, Prof and Hu, Guo-Qing, Prof and Xie, Fang-Yun, Prof and Sun, Yan, Prof and Chen, Xiao-Zhong, Prof and Li, Jin-Gao, Prof and Zhu, Xiao-Dong, Prof and Hu, Chao-Su, Prof and Xu, Xiang-Ying, Prof and Chen, Yuan-Yuan, MD and Hu, Wei-Han, Prof and Guo, Ling, Prof and Mo, Hao-Yuan, Prof and Chen, Lei, MD and Mao, Yan-Ping, MD and Sun, Rui, MD and Ai, Ping, MD and Liang, Shao-Bo, MD and Long, Guo-Xian, MD and Zheng, Bao-Min, MD and Feng, Xing-Lai, MD and Gong, Xiao-Chang, MD and Li, Ling, MD and Shen, Chun-Ying, MD and Xu, Jian-Yu, MD and Guo, Ying, PhD and Chen, Yu-Ming, Prof and Zhang, Fan, MD and Lin, Li, MD and Tang, Ling-Long, MD and Liu, Meng-Zhong, Prof and Ma, Jun, Dr Prof
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 11, pp. 1509 - 1520
Summary Background The value of adding cisplatin, fluorouracil, and docetaxel (TPF) induction chemotherapy to concurrent chemoradiotherapy in locoregionally... 
Hematology, Oncology and Palliative Medicine | 5-FLUOROURACIL | CISPLATIN | ONCOLOGY | PROGRESSION-FREE SURVIVAL | INTENSITY-MODULATED RADIOTHERAPY | CLINICAL-TRIALS | COMPARING NEOADJUVANT CHEMOTHERAPY | EXPERIENCE | FLUOROURACIL | DOCETAXEL | NECK-CANCER | Chemoradiotherapy - adverse effects | Nasopharyngeal Carcinoma | Carcinoma | Nasopharyngeal Neoplasms - mortality | Humans | Middle Aged | Nasopharyngeal Neoplasms - therapy | Docetaxel | Male | Cisplatin - administration & dosage | Induction Chemotherapy - adverse effects | Taxoids - administration & dosage | Fluorouracil - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adult | Female | Antimitotic agents | Yuan (China) | Medical colleges | Chemotherapy | Radiation | Antineoplastic agents | Cancer | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
by Miller, Vincent A, Prof and Hirsh, Vera, MD and Cadranel, Jacques, Prof and Chen, Yuh-Min, MD and Park, Keunchil, Prof and Kim, Sang-We, Prof and Zhou, Caicun, Prof and Su, Wu-Chou, Prof and Wang, Mengzhao, Prof and Sun, Yan, Prof and Heo, Dae Seog, Prof and Crino, Lucio, Prof and Tan, Eng-Huat, MD and Chao, Tsu-Yi, Prof and Shahidi, Mehdi, MD and Cong, Xiuyu Julie, PhD and Lorence, Robert M, MD and Yang, James Chih-Hsin, Prof
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 5, pp. 528 - 538
Summary Background Afatinib, an irreversible ErbB-family blocker, has shown preclinical activity when tested in EGFR mutant models with mutations that confer... 
Hematology, Oncology and Palliative Medicine | TYROSINE KINASE INHIBITORS | GROWTH-FACTOR RECEPTOR | ONCOLOGY | CLINICAL-TRIALS | MUTATION | ACQUIRED-RESISTANCE | QLQ-C30 | IRREVERSIBLE EGFR | III TRIAL | DISCONTINUATION | GEMCITABINE | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Double-Blind Method | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Lung Neoplasms - secondary | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Antimitotic agents | Medical colleges | Care and treatment | Chemotherapy | Analysis | Lung cancer | Metastasis | Lung cancer, Non-small cell | Antineoplastic agents | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial
by Chen, Lei, MD and Hu, Chao-Su, Prof and Chen, Xiao-Zhong, Prof and Hu, Guo-Qing, Prof and Cheng, Zhi-Bin, Prof and Sun, Yan, Prof and Li, Wei-Xiong, Prof and Chen, Yuan-Yuan, MD and Xie, Fang-Yun, MD and Liang, Shao-Bo, MD and Chen, Yong, MD and Xu, Ting-Ting, MD and Li, Bin, MD and Long, Guo-Xian, MD and Wang, Si-Yang, MD and Zheng, Bao-Min, MD and Guo, Ying, PhD and Sun, Ying, MD and Mao, Yan-Ping, MD and Tang, Ling-Long, MD and Chen, Yu-Ming, Prof and Liu, Meng-Zhong, Prof and Ma, Jun, Prof
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 2, pp. 163 - 171
Summary Background The effect of the addition of adjuvant chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma is... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | THERAPY | INDUCTION CHEMOTHERAPY | ONCOLOGY | SQUAMOUS-CELL CARCINOMA | II TRIAL | DATA METAANALYSIS | ADVANCED HEAD | CANCER | CISPLATIN-RADIOTHERAPY | Chemoradiotherapy - methods | Nasopharyngeal Carcinoma | Carcinoma | Follow-Up Studies | Humans | Middle Aged | Nasopharyngeal Neoplasms - therapy | Kaplan-Meier Estimate | Antineoplastic Combined Chemotherapy Protocols | Male | Cisplatin - administration & dosage | Young Adult | Disease-Free Survival | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Chemotherapy, Adjuvant - methods | Nasopharyngeal Neoplasms - epidemiology | China | Cisplatin - adverse effects | Female | Aged | Neoplasm Staging | Medical colleges | Care and treatment | Nuclear radiation | Adjuvant treatment | Clinical trials | Public health | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
by Shi, Yuankai, MD and Zhang, Li, MD and Liu, Xiaoqing, MD and Zhou, Caicun, MD and Zhang, Shucai, MD and Wang, Dong, MD and Li, Qiang, MD and Qin, Shukui, MD and Hu, Chunhong, MD and Zhang, Yiping, MD and Chen, Jianhua, MD and Cheng, Ying, MD and Feng, Jifeng, MD and Zhang, Helong, MD and Song, Yong, MD and Wu, Yi-Long, MD and Xu, Nong, MD and Zhou, Jianying, MD and Luo, Rongcheng, MD and Bai, Chunxue, MD and Jin, Yening, MD and Liu, Wenchao, MD and Wei, Zhaohui, PhD and Tan, Fenlai, MD and Wang, Yinxiang, PhD and Ding, Lieming, MD and Dai, Hong, MD and Jiao, Shunchang, MD and Wang, Jie, MD and Liang, Li, MD and Zhang, Weimin, MD and Sun, Yan, Prof
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 10, pp. 953 - 961
Summary Background Icotinib, an oral EGFR tyrosine kinase inhibitor, had shown antitumour activity and favourable toxicity in early-phase clinical trials. We... 
Hematology, Oncology and Palliative Medicine | RECEPTOR GENE-MUTATIONS | FAILED PREVIOUS CHEMOTHERAPY | ONCOLOGY | TYROSINE KINASE INHIBITOR | TIME | DOCETAXEL | III TRIAL | ERLOTINIB | EGFR | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Crown Ethers - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Crown Ethers - adverse effects | Female | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Antimitotic agents | Clinical trials | Medical colleges | Lung cancer, Non-small cell | Antineoplastic agents | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Effect of a training and educational intervention for physicians and caregivers on antibiotic prescribing for upper respiratory tract infections in children at primary care facilities in rural China: a cluster-randomised controlled trial
by Wei, Xiaolin and Zhang, Zhitong and Walley, John D and Hicks, Joseph P and Zeng, Jun and Deng, Simin and Zhou, Yu and Yin, Jia and Newell, James N and Sun, Qiang and Zou, Guanyang and Guo, Yan and Upshur, Ross E G and Lin, Mei
The Lancet Global Health, ISSN 2214-109X, 12/2017, Volume 5, Issue 12, pp. e1258 - e1267
Inappropriate antibiotic prescribing contributes to the generation of drug resistance worldwide, and is particularly common in China. We assessed the... 
PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | PROVINCE | PRIMARY-HEALTH-CARE | REDUCE | Inappropriate Prescribing - adverse effects | Humans | Child, Preschool | Male | Respiratory Tract Infections - drug therapy | Inappropriate Prescribing - prevention & control | Respiratory Tract Infections - diagnosis | Anti-Bacterial Agents - therapeutic use | Caregivers - education | Health Personnel - education | Rural Population | China | Adolescent | Female | Primary Health Care | Child
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text The Confucius Hometown Aging Project: a community-based study of ageing and health in a rural area
by Qiu, Chengxuan, Dr and Yan, Zhongrui, Prof and Cai, Chuanzhu, MD and Jiang, Hui, MD and Sun, Binglun, MD and Song, Aiqin, Prof and Liang, Yajun, PhD
Lancet, The, ISSN 0140-6736, 2015, Volume 386, pp. S57 - S57
Abstract Background Vascular risk factors (eg, smoking, hypertension, and diabetes) are associated with cognitive and physical dysfunction in old age. We... 
Internal Medicine | Hypertension
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Social Marketing Improved the Consumption of Iron-fortified Soy Sauce among Women in China
by Sun, Xinying, PhD and Guo, Yan, Prof and Wang, Sisun, MPH and Sun, Jing, MD
Journal of Nutrition Education and Behavior, ISSN 1499-4046, 2007, Volume 39, Issue 6, pp. 302 - 310
Abstract Objective To test the feasibility and effectiveness of social marketing on the improvement of women’s knowledge, attitudes, and behaviors regarding... 
Internal Medicine | Gastroenterology and Hepatology | iron deficiency | Health Belief Model | Theory of Planned Behavior | iron-fortified soy sauce | social marketing | FOLIC ACID SUPPLEMENTATION | COUNTRIES | CAMBODIAN WOMEN | PREVENT | COMMUNITY MOBILIZATION | IMPACT | NUTRITION & DIETETICS | ANEMIA | REPRODUCTIVE AGE | EDUCATION, SCIENTIFIC DISCIPLINES | Intervention | Urban Areas | Rural Areas | Nutrition | Behavior Change | Foreign Countries | Control Groups | Mass Media Role | Marketing | Experimental Groups | Health Programs | Health Promotion | China | Adults | Females | Statistical Analysis | Food | Program Effectiveness | T Test | Social Marketing | Rural Population - statistics & numerical data | Urban Population - statistics & numerical data | Health Promotion - methods | Humans | Middle Aged | Iron, Dietary - administration & dosage | Anemia, Iron-Deficiency - prevention & control | Health Knowledge, Attitudes, Practice | Health Behavior | Feasibility Studies | Soy Foods - statistics & numerical data | Analysis of Variance | Mass Media | Adult | Female | Food, Fortified - statistics & numerical data | Surveys and Questionnaires | Aged | Soy sauce | Nutritional aspects | Influence | Health attitudes | Enriched foods | Iron in the body | Research | Consumption data | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Extending thrombolysis to 4.5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data
by Campbell, BCV and Ma, H and Ringleb, PA and Parsons, MW and Churilov, L and Bendszus, M and Levi, CR and Hsu, C and Kleinig, TJ and Fatar, M and Leys, D and Molina, C and Wijeratne, T and Curtze, S and Dewey, HM and Barber, PA and Butcher, KS and De Silva, DA and Bladin, CF and Yassi, N and Pfaff, JAR and Sharma, G and Bivard, A and Desmond, PM and Schwab, S and Schellinger, PD and Yan, B and Mitchell, PJ and Serena, J and Toni, D and Thijs, V and Hacke, W and Davis, SM and Donnan, GA and ECASS-4 Investigator and EPITHET Investigator and EXTEND Investigator
LANCET, ISSN 0140-6736, 07/2019, Volume 394, Issue 10193, pp. 139 - 147
Background Stroke thrombolysis with alteplase is currently recommended 0-4.5 h after stroke onset. We aimed to determine whether perfusion imaging can identify... 
MISMATCH | MEDICINE, GENERAL & INTERNAL | MULTICENTER | ALTEPLASE | ACUTE ISCHEMIC-STROKE | REPERFUSION | DIFFUSION | TIME | ONSET
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Associations Between Outdoor Of PM2.5 With Cough and Wheeze Symptoms In Asthmatic Children In Korea
by Kim, Woo Kyung, Prof and Lee, Young Wook, Mrs and Yoon, Hae-Sun, Dr
Journal of Allergy and Clinical Immunology, The, ISSN 0091-6749, 2014, Volume 133, Issue 2, pp. AB98 - AB98
Allergy and Immunology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial
by Zhang, Pin, Prof and Sun, Tao, Prof and Zhang, Qingyuan, Prof and Yuan, Zhongyu, Prof and Jiang, Zefei, Prof and Wang, Xiao Jia, Prof and Cui, Shude, Prof and Teng, Yuee, Prof and Hu, Xi-Chun, Prof and Yang, Junlan, Prof and Pan, Hongming, Prof and Tong, Zhongsheng, Prof and Li, Huiping, Prof and Yao, Qiang, Prof and Wang, Yongsheng, Prof and Yin, Yongmei, Prof and Sun, Ping, Prof and Zheng, Hong, Prof and Cheng, Jing, Prof and Lu, Jinsong, Prof and Zhang, Baochun, MD and Geng, Cuizhi, Prof and Liu, Jian, Prof and Peng, Roujun, MD and Yan, Min, MD and Zhang, Shaohua, MD and Huang, Jian, MD and Tang, Li, PhD and Qiu, Rongguo, PhD and Xu, Binghe, Prof and BG01-1323L Study Grp and BG01-1323L study group
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 3, pp. 371 - 383
Summary Background Utidelone, a genetically engineered epothilone analogue, has shown promise as a potential treatment for breast cancer in phase 1 and 2... 
Hematology, Oncology and Palliative Medicine | EPOTHILONE | IXABEPILONE BMS-247550 | MONOTHERAPY | SOLID TUMORS | ANALOG | ONCOLOGY | BEVACIZUMAB | RESISTANCE | COMBINATION | III TRIAL | CHEMOTHERAPY | Capecitabine - administration & dosage | Breast Neoplasms - secondary | Prognosis | Follow-Up Studies | Neoplasm Invasiveness | Humans | Middle Aged | Salvage Therapy | Survival Rate | Breast Neoplasms - drug therapy | Young Adult | Taxoids - administration & dosage | Neoplasm Metastasis | Anthracyclines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Epothilones - administration & dosage | Adolescent | Adult | Female | Aged | Neoplasm Staging | Bridged-Ring Compounds - administration & dosage | Drug Resistance, Neoplasm - drug effects | Yuan (China) | Medical colleges | Anthracyclines | Genetically modified organisms | Clinical trials | Breast cancer | Genetic engineering | Metastasis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
by Kim, Edward S, MD and Hirsh, Vera, MD and Mok, Tony, Prof and Socinski, Mark A, Prof and Gervais, Radj, MD and Wu, Yi-Long, Prof and Li, Long-Yun, Prof and Watkins, Claire L, MSc and Sellers, Mark V, MSc and Lowe, Elizabeth S, MD and Sun, Yan, MD and Liao, Mei-Lin, Prof and Østerlind, Kell, MD and Reck, Martin, MD and Armour, Alison A, FRCR and Shepherd, Frances A, Prof and Lippman, Scott M, Prof and Douillard, Jean-Yves, Prof
Lancet, The, ISSN 0140-6736, 2008, Volume 372, Issue 9652, pp. 1809 - 1818
Summary Background Two phase II trials in patients with previously-treated advanced non-small-cell lung cancer suggested that gefitinib was efficacious and... 
Internal Medicine | GROWTH-FACTOR RECEPTOR | SUPPORTIVE CARE | MEDICINE, GENERAL & INTERNAL | THERAPY | ONCOLOGY | FUNCTIONAL ASSESSMENT | PREDICTORS | MUTATIONS | GENE COPY NUMBER | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Taxoids - therapeutic use | Antineoplastic Agents - adverse effects | Quinazolines - therapeutic use | Quinazolines - adverse effects | Survival Analysis | Aged, 80 and over | Quality of Life | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Taxoids - adverse effects | Complications and side effects | Docetaxel | Dosage and administration | Research | Comparative analysis | Gefitinib | Lung cancer, Non-small cell | Drug therapy | Studies | Chemotherapy | Lung cancer | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial
by Wu, Yi-Long, Prof and Lee, Jin Soo, MD and Thongprasert, Sumitra, MD and Yu, Chong-Jen, Prof and Zhang, Li, Prof and Ladrera, Guia, MD and Srimuninnimit, Vichien, MD and Sriuranpong, Virote, MD and Sandoval-Tan, Jennifer, MD and Zhu, Yunzhong, Prof and Liao, Meilin, Prof and Zhou, Caicun, MD and Pan, Hongming, MD and Lee, Victor, FRCR and Chen, Yuh-Min, PhD and Sun, Yan, MD and Margono, Benjamin, PhD and Fuerte, Fatima, MD and Chang, Gee-Chen, MD and Seetalarom, Kasan, MD and Wang, Jie, Prof and Cheng, Ashley, MBBS and Syahruddin, Elisna, PhD and Qian, Xiaoping, MD and Ho, James, MD and Kurnianda, Johan, SPPD and Liu, Hsingjin Eugene, MD and Jin, Kate, MD and Truman, Matt, MSc and Bara, Ilze, MD and Mok, Tony, Prof
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 777 - 786
Summary Background The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated chemotherapy and erlotinib significantly... 
Hematology, Oncology and Palliative Medicine | PHASE-III TRIAL | CARBOPLATIN-PACLITAXEL | 1ST-LINE TREATMENT | GEFITINIB | MULTICENTER | THERAPY | NSCLC | ONCOLOGY | ADENOCARCINOMA | OPEN-LABEL | EGFR | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Time Factors | DNA Mutational Analysis | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Administration, Intravenous | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Medical colleges | Care and treatment | Chemotherapy | Clinical trials | Lung cancer, Non-small cell | Antineoplastic agents | Tumors | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights